Key result
PCI for in-stent chronic total occlusions using drug-eluting stents yielded similar 5-year target vessel failure rates compared to de novo occlusions (11.0% vs 10.7%, P=0.99).
Why the study?
To compare PCI outcomes in relation to stent optimisation profiles between in-stent CTOs and de novo CTOs.
Does percutaneous coronary intervention for in-stent chronic total occlusion yield similar clinical outcomes compared to PCI for de novo chronic total occlusion?
Cohort (n=1,516)
Does percutaneous coronary intervention for in-stent chronic total occlusion yield similar clinical outcomes compared to PCI for de novo chronic total occlusion?
Absolute Event Rate: 11% vs 10.7%
p-value: p=0.99
PCI for in-stent chronic total occlusions using drug-eluting stents and IVUS guidance yields similar long-term clinical outcomes to PCI for de novo CTOs.
Stent optimization may support similar PCI outcomes in in-stent versus de novo CTOs; observational data leaves open need for randomized trials.
AIMS: The aim of this study was to compare percutaneous coronary intervention (PCI) outcomes in relation to stent optimisation profiles between in-stent chronic total occlusions (CTOs) and de novo CTOs. METHODS AND RESULTS: We evaluated 1,516 consecutive patients who underwent PCI for 147 in-stent CTOs (9.3%) and 1,439 de novo CTOs between 2007 and 2018. The primary endpoint was target vessel failure (TVF) consisting of a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularisation. The final post-stenting intravascular ultrasound (IVUS) images were analysed. Target lesion complexity reflected by the Japanese CTO score was similar, albeit calcification was more prevalent in de novo CTOs, whereas occlusion length >20 mm was more frequent in in-stent CTOs. The technical success (88.4% vs 87.5%, p=0.84) and in-hospital adverse event (1.4% vs 3.6%, p=0.26) rates were similar between CTO types. Among those who received drug-eluting stents, the five-year TVF (11.0% vs 10.7%, p=0.99) and target vessel revascularisation (4.2% vs 3.7%, p=0.81) rates were similar between groups. Total stent length, minimum stent area (5.4±1.8 vs 5.5±1.8 mm2, p=0.77), and maximal plaque burden of the reference segments were largely comparable between groups. CONCLUSIONS: In-stent CTO PCI with drug-eluting stents optimised by IVUS guidance offers as acceptable long-term clinical results as those achieved in de novo CTOs.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2020) conducted a cohort in Chronic total occlusions (CTOs) (n=1,516). PCI for in-stent CTOs vs. PCI for de novo CTOs was evaluated on Target vessel failure (TVF) consisting of a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularisation (p=0.99). PCI for in-stent chronic total occlusions using drug-eluting stents yielded similar 5-year target vessel failure rates compared to de novo occlusions (11.0% vs 10.7%, P=0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: